tradingkey.logo
tradingkey.logo
Search

Pacira Biosciences Inc

PCRX
Add to Watchlist
25.390USD
+0.360+1.44%
Close 07/02, 13:00ETQuotes delayed by 15 min
998.07MMarket Cap
201.65P/E TTM

TradingKey Stock Score of Pacira Biosciences Inc

Currency: USD Updated: 2026-07-02

Key Insights

Pacira Biosciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 36 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.67.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pacira Biosciences Inc's Score

Industry at a Glance

Industry Ranking
36 / 157
Overall Ranking
86 / 4565
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Pacira Biosciences Inc Highlights

StrengthsRisks
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 201.65, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 48.22M shares, decreasing 27.14% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
29.667
Target Price
+18.24%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Pacira Biosciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of Pacira Biosciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Pacira Biosciences Inc’s performance and outlook.

How do we generate the financial health score of Pacira Biosciences Inc?

To generate the financial health score of Pacira Biosciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Pacira Biosciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Pacira Biosciences Inc.

How do we generate the company valuation score of Pacira Biosciences Inc?

To generate the company valuation score of Pacira Biosciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Pacira Biosciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Pacira Biosciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Pacira Biosciences Inc.

How do we generate the earnings forecast score of Pacira Biosciences Inc?

To calculate the earnings forecast score of Pacira Biosciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Pacira Biosciences Inc’s future.

How do we generate the price momentum score of Pacira Biosciences Inc?

When generating the price momentum score for Pacira Biosciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Pacira Biosciences Inc’s prices. A higher score indicates a more stable short-term price trend for Pacira Biosciences Inc.

How do we generate the institutional confidence score of Pacira Biosciences Inc?

To generate the institutional confidence score of Pacira Biosciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Pacira Biosciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Pacira Biosciences Inc.

How do we generate the risk management score of Pacira Biosciences Inc?

To assess the risk management score of Pacira Biosciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Pacira Biosciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Pacira Biosciences Inc.